Correlation between hepatitis C viral load and hepatitis C Core antigenaemia among Egyptians

Kotb, Dalia; Esmail, Mona Abdel Monem; Abdelwahab, Sayed F.; Abdel‐Hamid, Mohamed

doi:10.26719/2017.23.4.280

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, Ergunay et al [33] revealed 75.8% sensitivity. A group of studies recorded sensitivity of more than 90%, ranging from 93.26 to 96.3% as documented by Kotb et al and Demircili et al [34,35]. Miedouge et al reported that HCVcAg sensitivity was 100% [36].…”

Section: Discussionmentioning

confidence: 92%

Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients

Elbrolosy

El-Hamouly

Eed

et al. 2021

Egypt Liver Journal

View full text Add to dashboard Cite

Background Successful eradication of hepatitis C virus (HCV) has great impact on the prognosis of HCV-related complications and the associated mortality. The development of the new direct-acting antiviral drugs (DAAs) has revolutionized the treatment of HCV infection. HCV core antigen (HCVcAg) is a recently developed marker that displayed a good correlation with HCV RNA assays. Our main objectives were to correlate between serum levels of HCVcAg and HCV RNA loads in chronic HCV patients as well as to explore the potential value of HCVcAg assay in predicting treatment response to the new DAAs. The study enrolled a total of 280 chronic HCV-infected patients scheduled to start the new regimen for treatment of chronic HCV by all-oral, interferon-free DAAs. According to the viral load, the studied individuals were arranged into three groups corresponding to mild, moderate, and sever viremia. Serum level of HCVcAg was determined by ELISA technique and HCV RNA viral loads were quantified using the real-time PCR system. The assays were performed three times for all participants: prior to initiation of treatment, at the end of treatment (week 12), and 3 months post-treatment cessation (week 24). Results A statistically significant difference between HCV RNA and HCVcAg baseline levels among different viremia groups was detected (P < 0.001). There was a significant positive correlation between HCV RNA and HCVcAg baseline values among all the studied cases (P < 0.05) with a correlation coefficient of 0.752, 0.976, and 1.00 respectively for mild, moderate, and severe viremia groups. 92.9% (260/280) of the studied patients achieved sustained virologic response, 3.6% (10/280) were non-responders, and 3.6% (10/280) had recurrent viremia/relapse as regards RT-PCR results. Conclusion HCVcAg is a promising alternative to HCV RNA assay. The ELISAs for HCVcAg proved excellent correlations with HCV RNA levels. Moreover, HCVcAg can be introduced as a simple and highly specific tool for monitoring the new DAA regimens particularly in low-resource settings.

show abstract

Section: Discussionmentioning

confidence: 92%

Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients

Elbrolosy

El-Hamouly

Eed

et al. 2021

Egypt Liver Journal

View full text Add to dashboard Cite

show abstract

“…Since, the cost of an HCV RNA assay is generally several-fold that of an HCVcAg assay (8,21); therefore, using HCVcAg assays instead of HCV RNA assays might reduce the cost of diagnosis and the time taken to obtain results, and improve patient follow-up in certain environments. In fact, the results of a study that compared an HCV RNA assay with an HCVcAg assay for the detection and quantification of HCV viremia in Egyptian participants led the authors to conclude that while the HCV RNA assay remains the gold standard for the diagnosis of an active HCV infection, an HCVcAg assay can be used when PCR is not available (22).…”

Section: Discussionmentioning

confidence: 99%

Clinical Evaluation of a Newly Developed Chemiluminescent Enzyme Immunoassay for Hepatitis C Virus Core Antigen in Japan

et al. 2019

View full text Add to dashboard Cite

Correlation between hepatitis C viral load and hepatitis C Core antigenaemia among Egyptians

Cited by 2 publications

References 18 publications

Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients

Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients

Clinical Evaluation of a Newly Developed Chemiluminescent Enzyme Immunoassay for Hepatitis C Virus Core Antigen in Japan

Contact Info

Product

Resources

About